y90 humanized anti-tac
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 1989 (NCT00001249)
Timeline
1980s
- Jan 1, 1989
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2 receptor alpha chainBINDING AGENT
IL2RA binding agent
- Peripheral myelin protein 22INHIBITOR
PMP22 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109366 ↗
Also known as
- anti-tac 90 y-hat
- y90 humanized anti-tac
- y90 radiolabeled anti-tac antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00001575 | Phase 1/Phase 2 (Phase 2) | Apr 1, 1997 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00001249 | Phase 1 | Dec 1, 1989 | National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 2 | 2 | 1989 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 1997 |
2 organizations
Page 1 / 1